New Era of ADME and Beyond (NE-ADME 2026)
June 10, 2026 at MODERNA
325 Binney St., Cambridge, MA 02142
 |
Plenary LectureAmit Kalgutkar, PhDSenior Research Fellow, Rare Diseases & Antivirals Therapeutic Areas DMPK Portfolio Lead at Pfizer Case Studies on Metabolism-Guided Drug Design |
||||
 |
Nikhil Pillai, PhDSenior Principal Scientist, Sanofi Machine Learning-Enabled Prediction of Human Pharmacokinetics for Early Drug Discovery |
 |
Bjorn HaldSenior Scientist II - Drug Metabolism, Novo Nordisk peptide discovery and development for the ADME/DMPK perspective/NN approach to functionalize peptides into drugs - Title TBA |
||
 |
Xiaohua Zhu, PhDSenior Director, DMPK at Nimbus Therapeutics Optimizing ADME/DMPK Strategy to Accelerate Drug Discovery |
 |
Sophie Tourdot, PhDAssociate Research Fellow, Immunogenicity Sciences Lead, Pfizer Immunogenicity Risk Assessment: Enabling Quality by Design in Therapeutic Protein Discovery and Development |
||
 |
Vaibhav Maheshwari, PhDAssociate Director, EMD Serono PROTAC's compound selection and translation strategy based on simple mathematical model |
 |
Stefanus Steyn, PhDResearch Fellow, Pfizer Addressing PROTAC Plasma Protein Binding Challenges |
||
Session I: AI, In-Silico Tools & Translational In Vitro Models
Session II: In-Vitro ADME & Modeling Approaches
Session III: NAMs, IVIVC Trends & Comparative MPS/Organ-On-Chip Platforms
Session IV: Navigating ADME & Translational Hurdles in the Beyond Rule of 5 Chemical Space